CN103524629A - Complete antigen of AG22 polypeptide, preparation method and antibody thereof - Google Patents
Complete antigen of AG22 polypeptide, preparation method and antibody thereof Download PDFInfo
- Publication number
- CN103524629A CN103524629A CN201310514525.2A CN201310514525A CN103524629A CN 103524629 A CN103524629 A CN 103524629A CN 201310514525 A CN201310514525 A CN 201310514525A CN 103524629 A CN103524629 A CN 103524629A
- Authority
- CN
- China
- Prior art keywords
- polypeptide
- complete antigen
- linking agent
- antibody
- keyhole limpet
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Landscapes
- Peptides Or Proteins (AREA)
Abstract
The invention relates to a complete antigen of AG22 polypeptide. The complete antigen of AG22 polypeptide is formed by coupling of AG22 polypeptide and a cross-linking agent activated keyholelimpethaemocyanin protein, wherein the sequence of the AG22 polypeptide is shown as SEQ ID No.1. The complete antigen of AG22 polypeptide has strong immunogenicity, and can be put into use as a complete antigen. The invention also discloses a preparation method of the complete antigen of the AG22 polypeptide, and an AG22 polypeptide complete antigen's antibody specifically bound to the complete antigen of AG22 polypeptide. The AG22 polypeptide complete antigen's antibody can be used for detection of mouse osteocalcin protein in serum or tissue.
Description
Technical field
The present invention relates to field of immunology, particularly relate to a kind of complete antigen and preparation method thereof and antibody of AG22 polypeptide.
Background technology
Bone Gla protein protein is secreted by scleroblast, and its content changes along with the variation at age, by the content of serum osteocalcin, can understand osteoblastic state, for osteoporotic judgement etc., has great importance.
AG22 polypeptide is one section of conserved sequence in Mouse Bone calcium fibroin matter molecule, through this section of polypeptide of sequential analysis, has antigenic polypeptide.Yet the immunogenicity of AG22 polypeptide self is lower, cannot come into operation as complete antigen.
Summary of the invention
Based on this, be necessary to provide a kind of complete antigen of AG22 polypeptide.
In addition, be also necessary to provide the preparation method of the complete antigen of this AG22 polypeptide, and with the antibody of the complete antigen specific binding of this AG22 polypeptide.
A complete antigen for AG22 polypeptide, the complete antigen of described AG22 polypeptide is formed by the keyhole limpet hemocyanin coupling of AG22 polypeptide and linking agent activation;
Wherein, the sequence of described AG22 polypeptide is the sequence shown in SEQ ID No.1, and described AG22 polypeptide is by the keyhole limpet hemocyanin coupling of halfcystine and the activation of described linking agent.
In one embodiment, the mol ratio of the keyhole limpet hemocyanin of described AG22 polypeptide and the activation of described linking agent is 800～1000:1.
In one embodiment, described linking agent is maleimide.
A preparation method for the complete antigen of polypeptide, comprises the steps:
The keyhole limpet hemocyanin of linking agent activation is provided, and with sodium phosphate buffer, the keyhole limpet hemocyanin of described linking agent activation is reconstructed, obtain the keyhole limpet hemocyanin solution of the linking agent activation after reconstruct;
AG22 polypeptide is provided, and described AG22 polypeptide is dissolved with coupling buffer or distilled water, obtain AG22 polypeptide solution;
Keyhole limpet hemocyanin solution and the described AG22 polypeptide solution of the linking agent activation after described reconstruct are mixed to rear abundant reaction, after separation and purification, obtain being formed by the keyhole limpet hemocyanin coupling of described AG22 polypeptide and the activation of described linking agent the complete antigen of AG22 polypeptide, wherein, the sequence of described AG22 polypeptide is the sequence shown in SEQ ID No.1, and described AG22 polypeptide is by the keyhole limpet hemocyanin coupling of halfcystine and the activation of described linking agent.
In one embodiment, the concentration of the keyhole limpet hemocyanin solution of described linking agent activation is 5mg/mL;
The concentration of described AG22 polypeptide solution is 8mg/mL.
In one embodiment, in the operation that the keyhole limpet hemocyanin solution that the linking agent after described reconstruct is activated and described AG22 polypeptide solution mix, the mol ratio of the keyhole limpet hemocyanin of described AG22 polypeptide and the activation of described linking agent is 800～1000:1.
In one embodiment, described linking agent is maleimide.
In one embodiment, after separation and purification, obtain being operating as of complete antigen that keyhole limpet hemocyanin coupling by the activation of described AG22 polypeptide and described linking agent forms AG22 polypeptide:
With 30mL, containing mass percent is 0.01% sodium azide PBS damping fluid balance Sephadex G-25M gel column, then to described Sephadex G-25M gel column, add reaction solution, described PBS damping fluid washing with cumulative volume 10mL, collect elutant, each 0.5mL～1.0mL that collects, under 280nm, measure absorbance, according to absorbance, collect containing albumen elutriant.
An antibody for the complete antigen of polypeptide, the complete antigen specific binding of the antibody of the complete antigen of described AG22 polypeptide and above-mentioned AG22 polypeptide.
A kind of antibody of complete antigen of AG22 polypeptide, the antibody of the complete antigen of described AG22 polypeptide is that the complete antigen of above-mentioned AG22 polypeptide is expressed the antibody obtaining as antigen after by immune system recognition, and the antibody of the complete antigen of described AG22 polypeptide is polyclonal antibody or monoclonal antibody.
In one embodiment, the antibody of the complete antigen of described AG22 polypeptide is the polyclonal antibody in rabbit source.
The complete antigen of this AG22 polypeptide has stronger immunogenicity, can be used as complete antigen and comes into operation.The antibody of the complete antigen of this AG22 polypeptide can or be organized the detection of small mouse Bone Gla protein protein for serum.
Accompanying drawing explanation
Fig. 1 is preparation method's the schema of complete antigen of the AG22 polypeptide of an embodiment;
Fig. 2 is the structural representation of the keyhole limpet hemocyanin of linking agent activation;
Fig. 3 is the structural representation of cysteine hydrochloride monohydrate;
Fig. 4 is the structural representation of 5,5'-, bis-sulphur two (2-nitrobenzoic acid);
Fig. 5 is the result figure that tires and obtain of the polyclonal antibody of the ELISA method complete antigen of measuring AG22 polypeptide.
Embodiment
For above-mentioned purpose of the present invention, feature and advantage can be become apparent more, below in conjunction with accompanying drawing, the specific embodiment of the present invention is described in detail.A lot of details have been set forth in the following description so that fully understand the present invention.But the present invention can implement to be much different from alternate manner described here, and those skilled in the art can do similar improvement without prejudice to intension of the present invention in the situation that, so the present invention is not subject to the restriction of following public concrete enforcement.
The complete antigen of the AG22 polypeptide of one embodiment, the complete antigen of this AG22 polypeptide is formed by the keyhole limpet hemocyanin coupling of AG22 polypeptide and linking agent activation.
AG22 polypeptide is one section of conserved sequence in Mouse Bone calcium fibroin matter molecule, through this section of polypeptide of sequential analysis, has antigenic polypeptide.
The sequence of AG22 polypeptide is the sequence shown in SEQ ID No.1, and AG22 polypeptide is by the keyhole limpet hemocyanin coupling of halfcystine and linking agent activation.
Keyhole limpet hemocyanin (KLH) molecular surface has a large amount of active groups, and what be most commonly used to coupling is primary amine group.Little polypeptide conventionally also can be for coupling with different groups, and conventional have primary amine group, carboxyl and a sulfydryl.
The coupling of polypeptide and KLH utilizes these groups exactly, then by linking agent (crosslinker), the sulfydryl/carboxyl/primary amine on polypeptide is connected with the primary amine on KLH, thereby forms covalent coupling, is prepared into complete antigen, for immune animal, obtains antibody.
So the primary amine of coupling should be to come from lysine side-chain and N end, the carboxyl of coupling comes from aspartic acid, L-glutamic acid and C end, and sulfydryl comes from halfcystine.
The quantity getting on as for coupling, and the peptide section adding, linking agent, the molar ratio of KLH is relevant.Conventionally may up to a hundred peptide sections of coupling on a part KLH.
In present embodiment, the mol ratio of AG22 polypeptide and keyhole limpet hemocyanin is 800～1000:1.
In present embodiment, linking agent is maleimide.
The preparation method of the complete antigen of above-mentioned AG22 polypeptide as shown in Figure 1, comprises the steps:
S10, the keyhole limpet hemocyanin that provides linking agent to activate, and with sodium phosphate buffer, the keyhole limpet hemocyanin of linking agent activation is reconstructed, the keyhole limpet hemocyanin solution of the linking agent activation after reconstruct obtained.
The structural representation of the keyhole limpet hemocyanin of linking agent activation as shown in Figure 2.
The sodium phosphate buffer pH adopting in present embodiment contains 20mM sodium phosphate, 230mM NaCl, 2mM EDTA and 80mM sucrose in 6.6,1mL sodium phosphate buffer.
In present embodiment, the concentration of the keyhole limpet hemocyanin solution of linking agent activation is 5mg/mL.
In present embodiment, linking agent is maleimide.
S20, provide AG22 polypeptide, and coupling buffer for AG22 polypeptide or distilled water are dissolved, obtain AG22 polypeptide solution.
In present embodiment, the concentration of AG22 polypeptide solution is 8mg/mL.
In present embodiment, the sodium phosphate buffer that coupling buffer can be 6.6 for the pH of the 20mM of the sucrose of EDTA, 80mM that contains 100mM and the NaCl of 230mM.
The keyhole limpet hemocyanin solution of the linking agent activation after S30, reconstruct that S10 is obtained and S20 must with AG22 polypeptide solution mix rear abundant reaction, after separation and purification, obtain being formed by the keyhole limpet hemocyanin coupling of AG22 polypeptide and linking agent activation the complete antigen of AG22 polypeptide.
Wherein, the sequence of described AG22 polypeptide is the sequence shown in SEQ ID No.1, and AG22 polypeptide is by halfcystine and keyhole limpet hemocyanin coupling.
In the operation that the keyhole limpet hemocyanin solution that linking agent after reconstruct is activated and AG22 polypeptide solution mix, the mol ratio of the keyhole limpet hemocyanin of AG22 polypeptide and linking agent activation is 800～1000:1.
After separation and purification, obtain being operating as of complete antigen that keyhole limpet hemocyanin coupling by the activation of AG22 polypeptide and linking agent forms AG22 polypeptide:
With 30mL, containing mass percent is 0.01% sodium azide PBS damping fluid balance Sephadex G-25M gel column, then to described Sephadex G-25M gel column, add reaction solution, described PBS damping fluid washing with cumulative volume 10mL, collect elutant, each 0.5mL～1.0mL that collects, under 280nm, measure absorbance, according to absorbance, collect containing albumen elutriant.
The complete antigen of this AG22 polypeptide has stronger immunogenicity, can be used as complete antigen and comes into operation.
The antibody of the complete antigen of the AG22 polypeptide of one embodiment, the complete antigen specific binding of the antibody of the complete antigen of this AG22 polypeptide and above-mentioned AG22 polypeptide.
The antibody of the complete antigen of the AG22 polypeptide of one embodiment, the antibody of the complete antigen of this AG22 polypeptide is that the complete antigen of above-mentioned AG22 polypeptide is expressed the antibody obtaining as antigen after by immune system recognition.The antibody of the complete antigen of this AG22 polypeptide is polyclonal antibody or monoclonal antibody.
Particularly, the antibody of the complete antigen of this AG22 polypeptide is the polyclonal antibody in rabbit source.
The antibody of the complete antigen of this AG22 polypeptide can or be organized the detection of small mouse Bone Gla protein protein for serum.
Down by specific embodiment, the complete antigen to above-mentioned AG22 polypeptide, the preparation method of the complete antigen of AG22 polypeptide, and with the antibody of the complete antigen specific binding of this AG22 polypeptide, be further explained and experimental results show that.
If no special instructions, the method adopting in embodiment is ordinary method, and in case study on implementation, agents useful for same material is routine biochemistry reagent.Quantitative test in following examples, all arranges and repeats experiment, results averaged for three times.
In embodiment, phosphate buffered saline buffer used is the PBS damping fluid of pH7.4,0.01M.In embodiment, carbonate buffer solution used is the sodium carbonate buffer of pH9.6,0.05M.
The medicine and the material that in embodiment, use comprise: bovine serum albumin is called for short BSA; Keyhole limpet hemocyanin is referred to as KLH; Cysteine hydrochloride monohydrate, molecular weight 175.6344, structural formula is as shown in Figure 3; 5,5'-, bis-sulphur two (2-nitrobenzoic acid) are called for short DTNB, molecular weight 396.35, and structural formula is as shown in Figure 4; New zealand white rabbit (4 monthly ages were purchased from Guangdong Province's Experimental Animal Center).
Embodiment 1
The preparation of the complete antigen of AG22 polypeptide.
1. the KLH that opens a pipe maleimide activation adds 1mL20mM sodium phosphate buffer, and (80mM sucrose, pH6.6), is reconstructed the KLH of maleimide activation, is prepared into the solution of 5mg/mL, uses as early as possible for 230mM NaCl, 2mM EDTA;
2. with 10mL distilled water, coupling buffer is reconstructed, prepare sodium phosphate buffer (100mM EDTA, 80mM sucrose, pH6.6);
3. the AG22 polypeptide that 4mg is contained to halfcystine is dissolved in 0.5mL coupling buffer or distilled water, leaves and takes 50 μ L polypeptide solutions for determining coupling efficiency (total cys) simultaneously, is saved to 2-8 ℃;
4. immediately AG22 polypeptide solution is mixed in reaction tubes with the KLH of maleimide activation, stir;
5. the lasting room temperature of stirring reaction is spent the night for 2 hours or 2-8 ℃;
6. retain 100 μ L linked reaction liquid for determining coupling efficiency (free cys).
Embodiment 2
The separation and purification of the complete antigen of AG22 polypeptide.
1. a bag PBS is dissolved in 1L distilled water, adds 0.01% sodium azide, prolonged preservation;
2. Sephadex G-25M gel column is fixed on suitable beaker;
3. take off the lid of gel column, cut off the bottom of gel column, allow excessive liquid flow out, forbid dried liquid stream in post;
4. with 30mL PBS balanced gel post, if do not use immediately gel column please build after upper and lower lid, be saved to 2-8 ℃;
5. to gel column, add reacted liquid, collect lower end flowing liquid;
6. with cumulative volume 10mL PBS washing, collect elutant, collect each time 0.5mL-1.0mL, under 280nm, measure absorbance;
7. collect containing albumen elutriant ,-20 ℃ frozen.
Embodiment 3
The drafting of C halfcystine typical curve.
1. a pipe DTNB damping fluid is dissolved in 10mL distilled water;
By 5mgDTNB agent dissolves in 5mLDTNB damping fluid;
3. 32mg Cys hydrochloride monohydrate is dissolved in 1mL distilled water to gradient dilution scope 0.4-0.04mg/mL;
4. in testing tube, add prediluted halfcystine reference liquid 50 μ L, blank tube adds 50 μ L distilled waters;
5. in all pipes, add 0.1mL distilled water, 0.75mL pH8.0DTNB damping fluid, adds 0.1mLDTNB reagent solution immediately, and making cumulative volume is 1mL, mixes;
6. at 412nm place, measure absorbance, production standard curve, in triplicate.
Embodiment 4
The mensuration of the complete antigen of AG22 polypeptide.
1. the AG22 polypeptide solution of 50 μ L (total cys) is added in 0.1mL distilled water;
2. following 50 μ L solution are added in testing tube: the polypeptide sample of DTNB damping fluid (blank), dilution (total cys, KLH combination), the free cys of polypeptide-K LH(, KLH in conjunction with), the polypeptide sample (total cys, BSA in conjunction with) of dilution, the free cys of polypeptide-BSA(, BSA in conjunction with);
3. to all 0.1mL distilled waters that in vitro add, the DTNB damping fluid of 0.75mLpH8.0, adds 0.1mLDTNB reagent solution immediately, and final volume is 1mL, mixes;
4. at 412nm place, measure absorbance, if absorbance is greater than 1.4, dilute sample repeated test;
5. calculation formula
% coupling efficiency=(the free cys of total cys-)/total cys*100.
It is 62% that the coupling that calculates the complete antigen of AG22 polypeptide is tired.
Embodiment 5
The mensuration of tiring of the polyclonal antibody of the complete antigen of animal immune and AG22 polypeptide.
The complete antigen of the AG22 polypeptide that separation and purification in embodiment 2 is obtained is by the immunity of new zealand white rabbit, immunity is four times altogether, first immunisation 600 μ g/ only, with complete Freund's adjuvant, carry out emulsification, subcutaneous multi-point injection, with 300 μ g/, only with formula Freund's incomplete adjuvant not, carry out emulsification afterwards, carry out primary immune response every two weeks, after last immunity, the mensuration that the polyclonal antibody of the complete antigen of AG22 polypeptide is tired is carried out in blood sampling.
Antibody titer is measured---ELISA method
1. antigen coated: the complete antigen of AG22 polypeptide is diluted to concentration 2 μ g/mL, adds 96 orifice plates, every hole 100 μ L, 4 ℃ of wet box endoperidiums spend the night;
2. washing: wash coated enzyme plate with the PBS damping fluid that contains 0.05% tween 20,200 μ L/ holes, wash 5min/ time 3 times;
3. sealing: with 1%BSA solution, 96 orifice plates are sealed 250 μ L/ holes, 37 ℃ of wet box inner sealing 2h;
4. washing: the same washing methods;
5. primary antibodie is hatched: by rabbit anteserum polyclonal antibody according to 1:1000,1:2000,1:4000,1:8000,1:16000,1:32000,1:64000 dilute with PBS damping fluid, blank and negative serum contrast are set simultaneously, and 100 μ L/ holes, hatch 1h in 37 ℃ of wet boxes;
6. washing: the same washing methods;
7. two anti-hatching: the goat anti-rabbit igg antibody of HRP mark is diluted according to 1:5000 with PBS damping fluid, and 100 μ L/ holes, hatch 1h in 37 ℃ of wet boxes;
8. washing: the same washing methods;
9. add substrate: TMB is added to 96 orifice plates according to 100 μ L/ holes, lucifuge reaction 20min in 37 ℃ of wet boxes;
10. termination reaction: use 2M H
2sO
4according to 50 μ L/ holes, add 96 orifice plate termination reactions, by microplate reader, measure absorbance, makings OD when the 450nm wavelength
positive/ OD
negative> 2.1 is serum titer criterion.
Measuring result as shown in Figure 5, as can be seen from Figure, the tiring as 1:32000 of the polyclonal antibody of the complete antigen of the AG22 polypeptide that this enforcement prepares.
The above embodiment has only expressed several embodiment of the present invention, and it describes comparatively concrete and detailed, but can not therefore be interpreted as the restriction to the scope of the claims of the present invention.It should be pointed out that for the person of ordinary skill of the art, without departing from the inventive concept of the premise, can also make some distortion and improvement, these all belong to protection scope of the present invention.Therefore, the protection domain of patent of the present invention should be as the criterion with claims.
Claims (11)
1. a complete antigen for AG22 polypeptide, is characterized in that, the complete antigen of described AG22 polypeptide is formed by the keyhole limpet hemocyanin coupling of AG22 polypeptide and linking agent activation;
Wherein, the sequence of described AG22 polypeptide is the sequence shown in SEQ ID No.1, and described AG22 polypeptide is by the keyhole limpet hemocyanin coupling of halfcystine and the activation of described linking agent.
2. the complete antigen of AG22 polypeptide according to claim 1, is characterized in that, the mol ratio of the keyhole limpet hemocyanin of described AG22 polypeptide and the activation of described linking agent is 800～1000:1.
3. the complete antigen of AG22 polypeptide according to claim 1, is characterized in that, described linking agent is maleimide.
4. a preparation method for the complete antigen of AG22 polypeptide, is characterized in that, comprises the steps:
The keyhole limpet hemocyanin of linking agent activation is provided, and with sodium phosphate buffer, the keyhole limpet hemocyanin of described linking agent activation is reconstructed, obtain the keyhole limpet hemocyanin solution of the linking agent activation after reconstruct;
AG22 polypeptide is provided, and described AG22 polypeptide is dissolved with coupling buffer or distilled water, obtain AG22 polypeptide solution;
Keyhole limpet hemocyanin solution and the described AG22 polypeptide solution of the linking agent activation after described reconstruct are mixed to rear abundant reaction, after separation and purification, obtain being formed by the keyhole limpet hemocyanin coupling of described AG22 polypeptide and the activation of described linking agent the complete antigen of AG22 polypeptide, wherein, the sequence of described AG22 polypeptide is the sequence shown in SEQ ID No.1, and described AG22 polypeptide is by the keyhole limpet hemocyanin coupling of halfcystine and the activation of described linking agent.
5. the preparation method of the complete antigen of AG22 polypeptide according to claim 4, is characterized in that, the concentration of the keyhole limpet hemocyanin solution of described linking agent activation is 5mg/mL;
The concentration of described AG22 polypeptide solution is 8mg/mL.
6. the preparation method of the complete antigen of AG22 polypeptide according to claim 4, it is characterized in that, in the operation that the keyhole limpet hemocyanin solution that linking agent after described reconstruct is activated and described AG22 polypeptide solution mix, the mol ratio of the keyhole limpet hemocyanin of described AG22 polypeptide and the activation of described linking agent is 800～1000:1.
7. the preparation method of the complete antigen of AG22 polypeptide according to claim 4, is characterized in that, described linking agent is maleimide.
8. the preparation method of the complete antigen of AG22 polypeptide according to claim 4, is characterized in that, obtains being operating as of complete antigen that keyhole limpet hemocyanin coupling by the activation of described AG22 polypeptide and described linking agent forms AG22 polypeptide after separation and purification:
With 30mL, containing mass percent is 0.01% sodium azide PBS damping fluid balance Sephadex G-25M gel column, then to described Sephadex G-25M gel column, add reaction solution, described PBS damping fluid washing with cumulative volume 10mL, collect elutant, each 0.5mL～1.0mL that collects, under 280nm, measure absorbance, according to absorbance, collect containing albumen elutriant.
9. an antibody for the complete antigen of AG22 polypeptide, is characterized in that, the complete antigen specific binding of the antibody of the complete antigen of described AG22 polypeptide and the AG22 polypeptide as described in any one in claim 1～3.
10. the antibody of the complete antigen of an AG22 polypeptide, it is characterized in that, the complete antigen that the antibody of the complete antigen of described AG22 polypeptide is AG22 polypeptide as described in any one in claim 1～3 is expressed the antibody obtaining as antigen after by immune system recognition, and the antibody of the complete antigen of described AG22 polypeptide is polyclonal antibody or monoclonal antibody.
The antibody of the complete antigen of 11. AG22 polypeptide according to claim 10, is characterized in that, the antibody of the complete antigen of described AG22 polypeptide is the polyclonal antibody in rabbit source.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310514525.2A CN103524629A (en) | 2013-10-25 | 2013-10-25 | Complete antigen of AG22 polypeptide, preparation method and antibody thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310514525.2A CN103524629A (en) | 2013-10-25 | 2013-10-25 | Complete antigen of AG22 polypeptide, preparation method and antibody thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103524629A true CN103524629A (en) | 2014-01-22 |
Family
ID=49927017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310514525.2A Pending CN103524629A (en) | 2013-10-25 | 2013-10-25 | Complete antigen of AG22 polypeptide, preparation method and antibody thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103524629A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109957005A (en) * | 2017-12-22 | 2019-07-02 | 深圳先进技术研究院 | Plain polypeptide artificial antigen of a kind of metabolism and preparation method thereof, antibody and application |
| CN109957006A (en) * | 2017-12-22 | 2019-07-02 | 深圳先进技术研究院 | A kind of plain polypeptide artificial antigen of metabolism and antibody and application |
-
2013
- 2013-10-25 CN CN201310514525.2A patent/CN103524629A/en active Pending
Non-Patent Citations (2)
| Title |
|---|
| NCBI: "AAH31815.1", 《GENBANK》 * |
| 吕凤林，等: "多肽疫苗佐剂的研究进展", 《细胞与分子免疫学杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109957005A (en) * | 2017-12-22 | 2019-07-02 | 深圳先进技术研究院 | Plain polypeptide artificial antigen of a kind of metabolism and preparation method thereof, antibody and application |
| CN109957006A (en) * | 2017-12-22 | 2019-07-02 | 深圳先进技术研究院 | A kind of plain polypeptide artificial antigen of metabolism and antibody and application |
| CN109957006B (en) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | Metabolin polypeptide artificial antigen, antibody and application |
| CN109957005B (en) * | 2017-12-22 | 2021-04-20 | 深圳先进技术研究院 | Metabolin polypeptide artificial antigen, preparation method thereof, antibody and application |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103554249A (en) | Complete antigen of AG15 polypeptide as well as preparation method and antibody thereof | |
| CN103509107B (en) | Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic polypeptide | |
| CN103509108B (en) | Method of preparing bombyx mori silk fibroin specific antibody by utilizing characteristic dodecapeptide | |
| CN102633864B (en) | GPC3 antigen polypeptide, anti-GPC3 polyclonal antibody and application thereof | |
| CN102305859B (en) | Activated toxic antibody kit for detecting porcine reproductive and respiratory syndrome virus | |
| CN102498217A (en) | Antibodies specific to E6 proteins of HPV and use thereof | |
| CN104031144A (en) | Antibody specifically binding to type 3, 4 hepatitis E viruses and application thereof | |
| CN109596839A (en) | People and peptide element fast quantitative measurement method for detecting and kit | |
| CN101936997B (en) | Human anti-rabies virus IgG antibody ELISA test kit | |
| CN110272502A (en) | The hybridoma and preparation method, monoclonal antibody and application of immunogene, the anti-cardiac muscle troponin I monoclonal antibody of secretion | |
| CN104865391B (en) | The anti-Seedling of people strangles the enzyme linked immunosorbent detection reagent of hormone | |
| CN113683702A (en) | Preparation method and application of polyclonal antibody of striped bamboo shark single-domain antibody | |
| CN106366193A (en) | Method of producing glycocholic acid polyclonal antibody with cholic acid as raw material | |
| CN103524629A (en) | Complete antigen of AG22 polypeptide, preparation method and antibody thereof | |
| CN104744580B (en) | A kind of TgVP1 extracellular regions antigen polypeptide, the polyclonal antibody of anti-TgVP1 and its application | |
| CN103524630A (en) | Complete antigen of OC22 polypeptide, preparation method and antibody thereof | |
| CN102336814B (en) | Polypeptide sequence for preparing anti-liver-neoplasm marker CK-19 antibody, polyclonal antibody and application thereof | |
| CN102690351B (en) | Preparation method of plasmodium vivax aldolase protein monoclonal antibody | |
| CN102539778A (en) | Enzyme linked immunosorbent assay kit for detecting recombinant human tumor necrosis factor-alpha | |
| CN104164407A (en) | Anti(pig erythrocyte CR1-like) monoclonal antibody and preparation thereof | |
| CN103694358A (en) | Locus specificity biotin labeled recombinant IgG (Intravenous Gamma Globulin) affine peptide and application thereof in IgG antibody three-dimensional oriented fixation | |
| CN103113455B (en) | Preparation and application of hemagglutinin peptide mark recombinant protein immunoaffinity purification enriching column | |
| CN104744581B (en) | A kind of toxoplasma protein TgVP1 intracellular regions antigen polypeptide, the polyclonal antibody of resisting toxoplasmosis TgVP1 and its application | |
| CN104311654A (en) | CIDE3 polypeptide, preparation of antibody thereof and applications of the antibody | |
| CN109678935A (en) | PCV3Cap proteantigen polypeptide, the polyclonal antibody of anti-PCV3 Cap protein and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20140122 |